Novartis Story

NVS -- USA Stock  

USD 84.44  0.53  0.63%

Macroaxis News
By Vlad Skutelnik
This post is geared to all Novartis management as well as to investors considering exiting their position in the enterprise. I will evaluate if Novartis shares are sensibly priced going into June and whether management should be worried. In defiance of conflicting performance in the last few months, the Stock's forward-looking signals remain relatively invariable which may send shares a bit higher in June 2019. The latest agitation may also be a sign of long running up-swing for the enterprise management. We found thirty-six available fundamentals for Novartis which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Novartis AG fundamentals including its Cash Flow from Operations, and the relationship between Cash and Equivalents and Market Capitalization . Given that Novartis AG has Price to Earning of 15.53X, we recommend you check Novartis last-minute market performance to make sure the company can sustain itself down the road. Use Novartis to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of Novartis to be traded at $85.97 in 30 days.
Does Novartis have anything left for June?

The company has 30.59B in debt with debt to equity (D/E) ratio of 64.6 . This implies that the stock may be unable to create cash to meet all of its financial commitments. Novartis AG has Current Ratio of 0.91 suggesting that it has not enough short term capital to pay financial commitments when the payables are due. This firm dividends can provide a clue to current valuation of the stock. Novartis one year expected dividend income is about $4.6 per share. The company has Net Profit Margin of 23.11 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.11 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income.

The entity has beta of 0.67. As returns on market increase, Novartis returns are expected to increase less than the market. However during bear market, the loss on holding Novartis will be expected to be smaller as well. The recent decline in stock price may encourage investors to take a closer look at the firm as it closed today at a share price of 81.05 on 2047050.000 in trading volume. The company directors and management have failed to build on market volatilities in April. However, diversifying your overall positions with Novartis may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.5287. The current volatility is consistent with the ongoing market swings in April 2019 as well as with Novartis AG unsystematic, company specific events. Novartis preserves 11.69% of shares owned by institutions. Novartis is trading at 81.88 which is 0.36% increase. Today lowest is 81.05. Novartis Average Assets is increasing over the last 5 years. Also, Novartis Earnings per Basic Share USD is increasing over the last 5 years. The latest value of Novartis Earnings per Basic Share USD is 5.01.

 2013 2014 2016 2018 2019 (projected)
Novartis Cost of Revenue 16,579,000,000  17,345,000,000  17,404,000,000  15,663,600,000  13,307,289,474 
Novartis Consolidated Income 9,292,000,000  10,280,000,000  17,794,000,000  16,014,600,000  12,028,631,579 

To conclude, our actual buy/sell recommendation on the enterprise is Hold. Novartis is currently undervalued with low probability of financial unrest for the next two years.

Novartis Revenue

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Novartis AG. Please refer to our Terms of Use for any information regarding our disclosure principles.

Story Momentum

This article from Macroaxis published on 16 of May contributed to the next trading period price escalation.The trading delta at closing time to the next next day price was 0.30% . The trading delta at closing time when the story was published to current price is 2.18% .

Similar stores for Novartis

2 days ago at 
Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point -
Thestreet News
Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point TheStreet.comFor his Executive Decision segment of Mad Money Tuesday night, Jim Cramer spoke with Vasant Narasimhan, CEO of Novartis AG , the drug maker with ...
few days ago at 
This Means More Growth Coming National Vision Holdings , Novartis AG - US Post News
This Means More Growth Coming National Vision Holdings , Novartis AG US Post NewsThe recent performance of National Vision Holdings stock in the market spoke loud and clear to investors as EYE saw more than 781.66K ...

Compare Novartis

Compare Novartis To Peers

Debt to Equity

Debt to Equity Comparative Analysis

  Debt to Equity 
      Novartis Comparables 
Novartis is rated below average in debt to equity category among related companies. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Please see also Novartis Hype Analysis, Novartis Correlation and Novartis Performance. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.